Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Lung cancer Clinical Trials

Protocol Number Title
Evaluating the Effectiveness of Reduced Nicotine Cigarettes, part of "Evaluating New Nicotine Standards for Cigarettes"
Benzo[a]pyrene Metabolism: Phenotyping and Genotyping Study 4: Deuterated Phenanthrene and NNK Cigarettes
CITN-06:A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
Molecular Analysis for Therapy Choice (MATCH)
COG ADVL1522 - A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma
COG AOST1421- A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
Phase 2, Parallel‐Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non‐Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal‐Epithelial Transition Factor
Pfizer A8081054: A Phase IB Study of Crizotinib in Combination with Pembrolizumab (MK-3475) in Patients with Untreated Advanced ALK-Translocated Non-Small Cell Lung Cancer
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Phase II Trial of Exemestane in Previously Treated Post-Menopausal Women with Advanced Non-Small Cell Lung Cancer
Investigation of kava effects on the metabolism of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in humans
EAY131-N: MATCH Treatment Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC

12 trials displayed